Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.
about
Combining radiotherapy with sunitinib: lessons (to be) learnedHampering immune suppressors: therapeutic targeting of myeloid-derived suppressor cells in cancerWays to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytesControl of the immune response by pro-angiogenic factorsSignal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapyMyeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacyInhibition of Fatty Acid Oxidation Modulates Immunosuppressive Functions of Myeloid-Derived Suppressor Cells and Enhances Cancer TherapiesModification of the tumor microenvironment as a novel target of renal cell carcinoma therapeuticsReduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors.Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer.The immunocytokine NHS-IL12 as a potential cancer therapeuticIntratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma.Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.Immune consequences of decreasing tumor vasculature with antiangiogenic tyrosine kinase inhibitors in combination with therapeutic vaccines.Melan-A/MART-1 immunity in a EWS-ATF1 translocated clear cell sarcoma patient treated with sunitinib: a case reportMDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.Sunitinib indirectly enhanced anti-tumor cytotoxicity of cytokine-induced killer cells and CD3⁺CD56⁺ subset through the co-culturing dendritic cells.The combination of a novel immunomodulator with a regulatory T cell suppressing antibody (DTA-1) regress advanced stage B16F10 solid tumor by repolarizing tumor associated macrophages in situ.Chronic inflammation and immunologic-based constraints in malignant disease.Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors.Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapyImmune consequences of tyrosine kinase inhibitors that synergize with cancer immunotherapyCombined Tbet and IL12 gene therapy elicits and recruits superior antitumor immunity in vivo.Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model.A rationally designed combined treatment with an alphavirus-based cancer vaccine, sunitinib and low-dose tumor irradiation completely blocks tumor development.Inhibition of the angiopoietin/Tie2 axis induces immunogenic modulation, which sensitizes human tumor cells to immune attack.Myeloid-derived suppressor cells adhere to physiologic STAT3- vs STAT5-dependent hematopoietic programming, establishing diverse tumor-mediated mechanisms of immunologic escape.Deficiency of Kruppel-like factor KLF4 in mammary tumor cells inhibits tumor growth and pulmonary metastasis and is accompanied by compromised recruitment of myeloid-derived suppressor cellsDLK1: a novel target for immunotherapeutic remodeling of the tumor blood vasculature.Immune-checkpoint blockade and active immunotherapy for glioma.Fallen angels or risen apes? A tale of the intricate complexities of imbalanced immune responses in the pathogenesis and progression of immune-mediated and viral cancers.Combination of sunitinib with anti-tumor vaccination inhibits T cell priming and requires careful scheduling to achieve productive immunotherapy.Control of the adaptive immune response by tumor vasculature.Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma.Role of myeloid-derived suppressor cells in tumor immunotherapy.Combining immunotherapy and targeted therapies in cancer treatment.Oncolytic virotherapy for renal cell carcinoma: a novel treatment paradigm?Strategies for enhancing vaccine-induced CTL antitumor immune responses.Modulation of immunity by antiangiogenic molecules in cancer.The potential role of sunitinib targeting melanomas.
P2860
Q26800587-EBE0945E-F7A4-46A1-9316-7BB955708AB6Q26863418-5429FFFB-ECCA-4273-B05A-56EDA58DBDF3Q26991991-2A893477-B88A-428B-B501-6C2F596FB33BQ27004733-12DCFEE4-A923-4C19-9C97-51E3B2022241Q28080262-3EF6216D-072C-45F2-BA86-CF83DB34C268Q28082461-AA163E51-CBD5-45D7-AFE7-512DF5FF6604Q28393381-977CD231-F17B-47B9-B3E8-5F4FEA0EFF4BQ28393614-9AF3D4E4-C58C-4D6D-BCFC-4FC9346B19B1Q30317831-52D56D0C-2037-444B-996C-F4D2A4B74380Q33606107-ED691622-44B7-4968-80D2-0A263221BCEBQ33688398-1B969EDC-0B53-4A93-BB1D-B9BEF02E2C5DQ33814322-9E78E412-FFC2-4C15-AE5A-E398403A9FF7Q34259974-E5433DEE-DF43-4177-8783-D6EF37552939Q34458617-A3F32392-B7CA-44B8-8CB1-E4A4AD6799DEQ34669336-15FB4B50-D3AC-4A58-8926-F35596DED349Q35028389-0C587C1A-4469-4AE5-AB47-BAD2AD5BC937Q35043102-6E89838B-21CC-4D9B-BBEC-9F174CAD9643Q35507095-871A5179-27AC-4AC6-A25F-1009E018694CQ35575974-CA4E516B-6E49-4476-B108-B6537D8206D7Q35580479-1CFE76C8-1B61-4D89-9E68-32C1C22221F1Q35597086-54503945-C181-4B73-A970-42BAC7AD6527Q35634179-7D25E169-6F85-47B3-91E7-C8E1FA78BBACQ35802152-AB4C6AB9-A9D4-4A22-8AA6-862D42B0D373Q35923178-73ADCB72-425A-48A5-8A4D-C9A496A60046Q36107975-804032AB-E29C-446B-A60F-73D24C6D1FD6Q36286833-411489E6-0840-4FA5-924B-D523CAC7DBDBQ37066106-CE856FAD-427B-4D53-8D82-56D8F1A40F0EQ37228480-9AF22260-5514-4043-8FE8-C45D463AF09BQ37254877-5F3DB4B7-FEA0-4E52-B8C2-FC368A679853Q37420586-6CD8C86A-1C72-4EBA-BB53-68B1324B20EBQ37620568-5A66EDFF-6C3D-4A59-9821-1645208AC68FQ37625756-D26896DE-4356-473F-B632-317F0A852FAEQ37683575-B1D15C7C-9A23-4ADC-ABF5-1DEF33E4D361Q37698857-61222A32-B544-4D68-9B4D-AC2F3BA10736Q37965750-C2EFBB5E-3E0C-49DB-AC13-E53FFC33910BQ37995939-B4BB57E1-E058-4445-8C4C-A01A1AABBED1Q38008023-6A03777C-D547-47E4-AF11-286D3A25ACBFQ38055143-79E60F0A-E809-4371-8032-AC199E49CBC2Q38074154-335DF8EA-EA17-4F5B-B40C-DBD5B44988F8Q38139560-21B85D9A-9EF5-43CD-AA90-B9F2D1545972
P2860
Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Sunitinib facilitates the acti ...... ert with specific vaccination.
@ast
Sunitinib facilitates the acti ...... ert with specific vaccination.
@en
type
label
Sunitinib facilitates the acti ...... ert with specific vaccination.
@ast
Sunitinib facilitates the acti ...... ert with specific vaccination.
@en
prefLabel
Sunitinib facilitates the acti ...... ert with specific vaccination.
@ast
Sunitinib facilitates the acti ...... ert with specific vaccination.
@en
P2093
P2860
P356
P1476
Sunitinib facilitates the acti ...... ert with specific vaccination.
@en
P2093
Anamika Bose
Brian I Rini
James H Finke
Jennifer L Taylor
Jennifer S Ko
Jorge A Garcia
Peter A Cohen
Sean Alber
Simon C Watkins
Walter J Storkus
P2860
P304
P356
10.1002/IJC.25863
P577
2011-05-25T00:00:00Z